TAK - Protalix Undervalued Due To Ghost Of Shire Upside On Fabry Approval Significant

What would you value a developing biotech with BLA submission just filed with the FDA? In this case, a BLA filed for a drug with the potential to outcompete a Sanofi (SNY) near-blockbuster, and the company is flush with cash after closing a $44M private placement. Somewhere near all-time lows? That's where Protalix BioTherapeutics (PLX) is, and to me, it looks unjustified, though understandable. If the FDA approves its BLA application for its Fabry disease drug, though, I believe the upside revaluation could be particularly significant.

Though there is one major

Read more ...